

ERK1/2 (Phospho-Thr202+Tyr204/Thr185+Tyr187) Antibody

Catalog No: #12548

Orders: order@signalwayantibody.comSupport: tech@signalwayantibody.com

Package Size: #12548-1 50ul #12548-2 100ul

Description

Product Name	ERK1/2 (Phospho-Thr202+Tyr204/Thr185+Tyr187) Antibody
Host Species	Rabbit
Clonality	Polyclonal
Purification	Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatography using non-phosphopeptide.
Applications	WB
Species Reactivity	Hu Ms Rt
Specificity	ERK1/2 (Phospho-Thr202+Tyr204/Thr185+Tyr187) Antibody detects endogenous levels of ERK1/2 (Thr202+Tyr204/Thr185+Tyr187) only when phosphorylated at Thr202+Tyr204/Thr185+Tyr187
Immunogen Type	Peptide
Immunogen Description	A synthesized peptide derived from human ERK1/2 (Phospho-Thr202+Tyr204/Thr185+Tyr187)
Target Name	ERK1/2
Modification	Phospho
Other Names	MAPK3, ERK-1, ERT2, HUMKER1A, HS44KDAP, MAP kinase 1, MAP kinase isoform p44, MAPK 1, MAPK 3, p44, p44MAPK, p44-MAPK, p44ERK1, Insulin-stimulated MAP2 kinase, MAP kinase 3, p44-ERK1, ERK1, PRKM3
Accession No.	Swiss-Prot#: P27361/P28482NCBI Gene ID: 5595/5594
Target Species	human
Calculated MW	42kd,44kd
Concentration	1.0mg/ml
Formulation	Rabbit IgG in phosphate buffered saline (without Mg ²⁺ and Ca ²⁺), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.
Storage	Store at -20°C

Application Details

Western blotting: 1:1000

Published Papers

el at., Inhibition of TMEM16A by Natural Product Silibinin: Potential Lead Compounds for Treatment of Lung Adenocarcinoma. In Front Pharmacol on 2021 Apr 14 by Shuai Guo, Xue Bai, et al..PMID:33935737, , (2021)

[PMID:33935737](https://pubmed.ncbi.nlm.nih.gov/33935737/)

el at., TMEM16A, a Homoharringtonine Receptor, as a Potential Endogenic Target for Lung Cancer Treatment. In Int J Mol Sci on 2021 Oct 10 by Shuai Guo, Xue Bai, et al..PMID:34681590, , (2021)

[PMID:34681590](https://pubmed.ncbi.nlm.nih.gov/34681590/)

el et al., TMEM16A-inhibitor loaded pH-responsive nanoparticles: A novel dual-targeting antitumor therapy for lung adenocarcinoma. In *Biochem Pharmacol*

on 2020 Aug by Shuai Guo, Liang Qiu, et al.. PMID:32492446, (2020)

[PMID:32492446](#)

Note: This product is for in vitro research use only and is not intended for use in humans or animals.